# OnCo record rejuv-second-alkylating-agents-and-myeloid-neoplasms (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "rejuv-second-alkylating-agents-and-myeloid-neoplasms" ;
  schema:name "Alkylating agents and therapy-related myeloid neoplasms"@en ;
  schema:alternateName "t-MDS"@en, "t-AML"@en, "Therapy-related myelodysplastic syndrome"@en, "Secondary leukaemia after chemotherapy"@en ;
  schema:description "Alkylating chemotherapy can damage a blood stem cell in a way that shows up years later as myelodysplastic syndrome or acute myeloid leukaemia. It is uncommon, it depends on the total dose, and the risk falls away after about ten years. Knowing the cumulative dose you were given is the single most useful thing on your treatment summary."@en ;
  schema:url <https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Alkylating_antineoplastic_agent> ;
  schema:citation <https://doi.org/10.1182/blood-2002-11-3343>, <https://doi.org/10.1200/JCO.2003.03.114>, <https://doi.org/10.1001/jamaoncol.2018.5625>, <https://doi.org/10.3324/haematol.11034>, <https://doi.org/10.1038/sj.leu.2405078> ;
  onco:tag "rejuvenation", "survivorship", "second-cancers", "blood", "chemotherapy" ;
  onco:related <https://onco.cc/terms/rejuv-second-cancers-overview/>, <https://onco.cc/terms/rejuv-second-topoisomerase-inhibitors-short-latency/>, <https://onco.cc/terms/rejuv-second-platinum-and-parp-inhibitors/>, <https://onco.cc/terms/rejuv-second-from-clone-to-disease/>, <https://onco.cc/terms/rejuv-second-choices-made-at-treatment/>, <https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml-secondary/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:drugs <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/mechlorethamine/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-survivorship/> .